Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2022 > Vol 3, №5 (2022) > What is known about the impact of hypertension on the course of COVID-19

What is known about the impact of hypertension on the course of COVID-19

Marina V. Moiseeva1 , Natalia V. Bagisheva , Anna V. Mordyk1 , Ekaterina G. Dzhusoeva , Ekaterina P. Antipova , Egor D. Marchenko

For citation:


  • Abstract
  • About the Author
  • References

Abstract

The aim of this work was an attempt to systematize the data available in the available literature and the course of coronavirus infection (coVId-19) in patients with arterial hypertension. It is known that hypertension is the most common disease, especially among older and elderly people. As predictors of an unfavorable course or progression of coronavirus infection, the authors indicate age, the level of increase in systolic blood pressure, as a predictor of vascular wall stiffness and endothelial dysfunction, and angiotensin-converting enzyme also plays a separate role. The lack of consensus on the impact of arterial hypertension on the course of coVId-19 requires a study of both hypertension itself and the components of antihypertensive therapy on the prognosis of the disease. 
Key words: arterial hypertension, coVId-19, course 


About the Author

Marina V. Moiseeva1 1 , Natalia V. Bagisheva 1 , Anna V. Mordyk1 2 , Ekaterina G. Dzhusoeva 1 , Ekaterina P. Antipova 1 , Egor D. Marchenko 1

1 Omsk State Medical University, Omsk, Russia

2 Omsk State Medical University, Omsk, Russia; National Medical Research Renter for Phthisiopulmonology and Infectious Diseases, Moscow, Russia

References

1. Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med 2020; 8: 430–2. DOI: 10.1016/S2213-2600(20)30165-X
2. Deng G, Yin M, Chen X et al. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care 2020; 24: 179. DOI: 10.1186/s13054-020-02902-w
3. Reynolds HR, Adhikari S, Pulgarin C et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; 382 (25): 2441–8. DOI: 10.1056/NEJMoa2008975
4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398 (10304): 957–80. DOI: 10.1016/S0140-6736(21)01330-1
5. Iaccarino G, Grassi G, Borghi C et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS Study of the Italian Society of hypertension. Hypertension 2020; 76: 366–72. DOI: 10.1161/HYPERTENSIONAHA.120.15324
6. Mancusi C, Grassi G, Borghi C et al. Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of hypertension. J Hypertens 2021; 39: 376–80. DOI: 10.1097/HJH.0000000000002666
7. Docherty AB, Harrison EM, Green CA et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 2020; 369: 1985. DOI: 10.1136/bmj.m1985
8. Caillon A, Zhao K, Klein KO et al. High systolic blood pressure at hospital admission is an important risk factor in models predicting outcome of COVID-19 patients. Am J Hypertens 2021; 34 (3): 282–90. DOI: 10.1093/ajh/hpaa225
9. Savoia C, Volpe M, Kreutz R. Hypertension, a moving target in COVID-19: current views and perspectives. Circ Res 2021; 128 (7): 1062–79. DOI: 10.1161/CIRCRESAHA.121.318054
10. Rodilla E, López-Carmona MD, Cortes X et al. Impact of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain. Hypertension 2021; 77 (3): 856–67. DOI: 10.1161/
hypertensionaha.120.16563
11. Kreutz R, Dobrowolski P, Prejbisz A et al. Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. J Hypertens 2021; 39 (6): 1077–89. DOI: 10.1097/HJH.0000000000002770
12. Volpe M, Gallo G. COVID-19 and the forgotten majority. High Blood Press Cardiovasc Prev 2020; 27 (5): 339. DOI: 10.1007/s40292-020-00407-9
13. Safar ME, Asmar R, Benetos A et al.; French Study Group on Arterial Stiffness. Interaction between hypertension and arterial stiffness. Hypertension 2018; 72: 796–805. DOI: 10.1161/hypertensionaha. 118.11212
14. Battistoni A, Michielon A, Marino G et al. Vascular aging and central aortic blood pressure: from pathophysiology to treatment. High Blood Press Cardiovasc Prev 2020; 27: 299–308. DOI: 10.1007/s40292-020-00395-w
15. Lala A, Johnson KW, Januzzi JL et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 2020; 76: 533–46. DOI: 10.1016/j.jacc.2020.06.007
16. Braun F, Lütgehetmann M, Pfefferle S et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 2020; 396 (10251): 597–8. DOI: 10.1016/S0140-6736(20)31759-1
17. WHO. Coronavirus disease 2019 (COVID-19) Situation Dashboard. Available at: https://covid19.who.int. Accessed: 14.11.2022.
18. Medetalibeyoglu A, Emet S, Kose M et al. Serum endocan levels on admission are associated with worse clinical outcomes in COVID-19 patients: a pilot study. Angiology 2021; 2: 187–93. DOI: 10.1177/ 0003319720961267
19. Akpek M. Does COVID-19 Cause Hypertension? Angiology 2022; 73 (7): 682–7. DOI: 10.1177/00033197211053903
20. Wan S, Yi Q, Fan S et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol 2020; 3: 428–37. DOI: 10.1111/bjh.16659
21. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 15: 762–8. DOI: 10.1093/cid/ciaa248
22. Imam Z, Odish F, Gill I et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 4: 469–76. DOI: 10.1111/joim.13119
23. Tadic M, Cuspidi C, Grassi G et al. COVID‐19 and arterial hypertension: hypothesis or evidence? J Clin Hypertens 2020; 22: 1120–6. DOI: 10.1111/jch.13925
24. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 2020; 130: 304–9. DOI: 10.20452/pamw.15272
25. Iheanacho CO, Odili VU, Eze UIH. Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of renin-angiotensin-aldosterone system (RAAS) inhibitors: a systematic review. Future J Pharm Sci 2021; 7: 73. DOI: 10.1186/s43094-021-00224-4
26. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. J Card Fail 2020; 26: 370. DOI: 10.1016/j.cardfail.2020.04.013
27. European Societies of Cardiology. Position Statement of ESC Council on Hypertension on ACE Inhibitors and Angiotensin Receptor Blockers. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed: 14.11.2022. 
28. Gheblawi M, Wang K, Viveiros A et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020; 10: 1456–74.  DOI: 10.1161/CIRCRESAHA.120.317015
29. Patel VB, Zhong J-C, Grant MB et al. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 2016; 118: 1313–26. DOI: 10.1161/CIRCRESAHA.116.307708
30. Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2. Circulation 2020; 142: 426–8. DOI: 10.1161/circulationaha. 120.047049
31. Liu Y, Yang Y, Zhang C et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 3: 364–74. DOI: 10.1007/s11427-020-1643-8
32. Гриневич В.Б., Губонина И.В., Дощицин В.Л. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020; 19 (4): 2630. DOI: 10.15829/1728-8800-2020-2630
[Grinevich V.B., Gubonina I.V., Doshchitsin V.L. et. al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-88002020-2630 (in Russian).]
33. Трухан Д.И., Давыдов Е.Л. Место и роль терапевта и врача общей практики в курации коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19): акцент на реабилитационный этап. Фарматека. 2021; 13: 44–53. DOI: 10.18565/pharmateca.2021.13.44-53
[Trukhan D.I., Davydov E.L. Mesto i rol' terapevta i vracha obshchei praktiki v kuratsii komorbidnykh patsientov v period pandemii novoi koronavirusnoi infektsii (COVID-19): aktsent na reabilitatsionnyi etap. Farmateka. 2021; 13: 44–53. DOI: 10.18565/pharmateca.2021.13.44-53 (in Russian).]
34. Трухан Д.И., Филимонов С.Н., Темникова Е.А. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. Гериатрические аспекты в кардиологии. СПб.: СпецЛит, 2022. Режим доступа: https://elibrary.ru/item.asp?id=48110916
[Trukhan D.I., Filimonov S.N., Temnikova E.A. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. Geriatricheskie aspekty v kardiologii. St. Petersburg: SpetsLit, 2022. Rezhim dostupa: https://elibrary.ru/item.asp?id=48110916 (in Russian).]


For citation:Moiseeva M.V., Bagisheva N.V., Mordyk A.V., Dzhusoeva E.G., Antipova E.P., Marchenko E.D. What is known about the impact of hypertension on the course of COVId-19. clinical analysis in general medicine. 2022; 5: 6–9. doI: 10.47407/kr2022.3.5.00156


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru